TY - JOUR
T1 - Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis
T2 - Screening and Baseline Survey Data from a Clinical Trial
AU - Weyne, Jonathan
AU - Blauvelt, Andrew
AU - de Bruin-Weller, Marjolein
AU - Prens, Errol
AU - Asbell, Penny
AU - Sierka, Debra
AU - Chen, Zhen
AU - Shumel, Brad
N1 - Funding Information:
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier NCT02260986. The study sponsors have funded the Journal’s Rapid Service fee for this paper.
Funding Information:
The authors thank the patients and their families for their participation in this study; their colleagues for their support; and Linda Williams (Regeneron Pharmaceuticals, Inc.), and Adriana Mello and El-Bdaoui Haddad (Sanofi Genzyme) for their contributions. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier NCT02260986. The study sponsors have funded the Journal?s Rapid Service fee for this paper. Medical writing/editorial assistance provided by Vicki Schwartz, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Content included in this manuscript was previously accepted for a poster presentation at the Society for Investigative Dermatology (SID) 2020 Annual Meeting; May 13?16, 2020.
Funding Information:
Medical writing/editorial assistance provided by Vicki Schwartz, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - INTRODUCTION: Patients with atopic dermatitis (AD) have a greater risk of conjunctivitis and other ocular surface disorders than the general population. We evaluated the burden of ocular surface disorders and related symptoms prior to treatment initiation in adults with moderate-to-severe AD.METHODS: Patients were enrolled in a randomized, placebo-controlled, double-blinded, phase 3 trial of dupilumab administered with concomitant topical corticosteroids. At the beginning of the screening period, all enrolled patients completed a survey of ocular disorder diagnoses received in the past year; at baseline, patients completed a survey of frequency and severity of ocular symptoms (discomfort, itching, redness, and tearing) experienced in the past month.RESULTS: A total of 712 of 740 patients enrolled in the trial provided responses to the survey. At screening, 286 of 740 patients (38.6%) reported having at least one ocular disorder in the past year. At baseline, 499 of 712 respondents (70.1%) reported having at least one symptom within the past month. Of these patients, 4.4%, 6.0%, 5.5%, and 4.4%, respectively, reported having discomfort, itching, redness, and tearing all of the time. Mild discomfort, itching, redness, and tearing were reported by 26.1%, 33.7%, 30.8%, and 31.6% of patients, respectively, while 7.3%, 7.7%, 6.2%, and 4.2%, reported severe discomfort, itching, redness, and tearing, respectively.CONCLUSIONS: These data demonstrate a high burden of ocular surface disorders and related symptoms in a population of adults with moderate-to-severe AD. Dermatologists should be aware of increased incidence of these disorders in AD and query their patients for signs and symptoms of eye disease. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT02260986.
AB - INTRODUCTION: Patients with atopic dermatitis (AD) have a greater risk of conjunctivitis and other ocular surface disorders than the general population. We evaluated the burden of ocular surface disorders and related symptoms prior to treatment initiation in adults with moderate-to-severe AD.METHODS: Patients were enrolled in a randomized, placebo-controlled, double-blinded, phase 3 trial of dupilumab administered with concomitant topical corticosteroids. At the beginning of the screening period, all enrolled patients completed a survey of ocular disorder diagnoses received in the past year; at baseline, patients completed a survey of frequency and severity of ocular symptoms (discomfort, itching, redness, and tearing) experienced in the past month.RESULTS: A total of 712 of 740 patients enrolled in the trial provided responses to the survey. At screening, 286 of 740 patients (38.6%) reported having at least one ocular disorder in the past year. At baseline, 499 of 712 respondents (70.1%) reported having at least one symptom within the past month. Of these patients, 4.4%, 6.0%, 5.5%, and 4.4%, respectively, reported having discomfort, itching, redness, and tearing all of the time. Mild discomfort, itching, redness, and tearing were reported by 26.1%, 33.7%, 30.8%, and 31.6% of patients, respectively, while 7.3%, 7.7%, 6.2%, and 4.2%, reported severe discomfort, itching, redness, and tearing, respectively.CONCLUSIONS: These data demonstrate a high burden of ocular surface disorders and related symptoms in a population of adults with moderate-to-severe AD. Dermatologists should be aware of increased incidence of these disorders in AD and query their patients for signs and symptoms of eye disease. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT02260986.
KW - Atopic dermatitis
KW - Burden
KW - Ocular disorders
KW - Survey
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=85092451342&partnerID=8YFLogxK
U2 - 10.1007/s13555-020-00456-x
DO - 10.1007/s13555-020-00456-x
M3 - Article
C2 - 33047298
SN - 2193-8210
VL - 10
SP - 1415
EP - 1421
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 6
ER -